Opus Genetics Inc. (IRD)
Company Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.
Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications.
The company was formerly known as Ocuphire Pharma, Inc.
Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
| Country | United States |
| IPO Date | Jan 19, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | George Magrath M.B.A., M.D., M.S. |
Contact Details
Address: 37000 Grand River Avenue Farmington Hills, Michigan United States | |
| Website | https://opusgtx.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US67577R1023 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| George Magrath M.B.A., M.D., M.S. | Chief Executive Officer & Director |
| Joseph K. Schachle MBA | Chief Operating Officer |
| Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer |
| Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance |
| Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development & Secretary |
| Bindu Manne | Head of Market Development & Commercialization |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific & Development Officer |
| Erik Sims | Director & Corporate Controller |